lactic acid has been researched along with Angina, Unstable in 4 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Objective of the present investigation was to enhance the bioavailability of felodipine by targeting the M cells of Peyer's patches using PLGA nanoparticles (NPs)." | 1.40 | Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. ( Joshi, G; Sawant, K; Shah, U, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, U | 1 |
| Joshi, G | 1 |
| Sawant, K | 1 |
| Vanhanen, I | 1 |
| Håkanson, E | 1 |
| Jorfeldt, L | 1 |
| Svedjeholm, R | 1 |
| Mohri, M | 1 |
| Koyanagi, M | 1 |
| Egashira, K | 1 |
| Tagawa, H | 1 |
| Ichiki, T | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Wu, ZK | 1 |
| Pehkonen, E | 1 |
| Laurikka, J | 1 |
| Kaukinen, L | 1 |
| Honkonen, EL | 1 |
| Kaukinen, S | 1 |
| Tarkka, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomised Controlled Trial of the Effect of Remote Ischaemic Conditioning on Coronary Endothelial Function in Patients With Angina.[NCT02666235] | Phase 2 | 60 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
2 trials available for lactic acid and Angina, Unstable
| Article | Year |
|---|---|
Myocardial uptake and release of substrates in patients operated for unstable angina: impact of glutamate infusion.
Topics: Aged; Angina, Unstable; Female; Glutamic Acid; Hemodynamics; Humans; Lactic Acid; Middle Aged; Myoca | 2003 |
Myocardial lactate production is not involved in the ischemic preconditioning mechanism in coronary artery bypass graft surgery patients.
Topics: Aged; Angina Pectoris; Angina, Unstable; Cardiac Output; Cardiopulmonary Bypass; Coronary Artery Byp | 2001 |
2 other studies available for lactic acid and Angina, Unstable
| Article | Year |
|---|---|
Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design.
Topics: Absorption; Administration, Oral; Angina, Unstable; Animals; Antihypertensive Agents; Cardiotonic Ag | 2014 |
Angina pectoris caused by coronary microvascular spasm.
Topics: Acetylcholine; Aged; Angina, Unstable; Coronary Angiography; Coronary Artery Disease; Coronary Circu | 1998 |